Orphan drug reimbursement should consider more than cost, says Eurordis
This article was originally published in SRA
Executive Summary
The European rare disease association Eurordis has called on drug reimbursement authorities to bear in mind that while orphan medicines may be expensive, there are relatively few of them and they will be taken by very small numbers of patients1.